Monopar Therapeutics Inc (MNPR) USD0.001

Sell:$79.25Buy:$100.00$0.33 (0.40%)

Prices delayed by at least 15 minutes
Sell:$79.25
Buy:$100.00
Change:$0.33 (0.40%)
Deal now
Prices delayed by at least 15 minutes
Sell:$79.25
Buy:$100.00
Change:$0.33 (0.40%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.

Key people

Christopher M. Starr
Executive Chairman of the Board
Chandler D. Robinson
Chief Executive Officer, Director
Quan A. Vu
Chief Financial Officer, Principal Accounting Officer
Andrew J. Cittadine
Chief Operating Officer
Patrice P. Rioux
Acting Chief Medical Officer
Kim R. Tsuchimoto
Director
Raymond William Anderson
Independent Director
Arthur J. Klausner
Independent Director
Lavina Talukdar
Independent Director
Click to see more

Key facts

  • Shares in issue
    6.61m
  • EPIC
    MNPR
  • ISIN
    US61023L2079
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • Market cap
    $537.13m
  • Employees
    16
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.